A New Look at Treating Some Old Mental Disorders

By McCann, Jean | Drug Topics, June 17, 2002 | Go to article overview
Save to active project

A New Look at Treating Some Old Mental Disorders

McCann, Jean, Drug Topics



The American Academy of Pediatrics has now officially classified attention deficit hyperactivity disorder (ADHD) as a chronic disease. Thus, much attention is being paid to treating the condition with drugs that are safe and effective over the long term.

ADHD is but one of several mental disorders increasingly being treated with drugs rather than just talk therapy. New findings about the drug treatments for anxiety, depression, bipolar disorder, schizophrenia, and other less-common mental disorders also occupied psychiatrists as they met recently in Philadelphia for the annual meeting of the American Psychiatric Association (APA). Below are reports on what's new.


This combination of inattention plus hyperactivity and impulsivity is seen in an estimated 3% to 5% of schoolchildren-mostly boys-and in some cases continuing into adulthood. For many years, methylphenidate has been the standard therapy. Now there are new extended-release formulations of the drug that appear to improve compliance, without serious side effects.

Timothy Wilens, M.D., associate professor of psychiatry at Harvard Medical School, studied 240 children aged six through 13 in a multicenter, open-label trial of once-daily extended-release methylphenidate (Concerta, Alza), at doses of 18, 36, or 54 mg. He said he found that the drug did not adversely affect height, weight, or vital signs and did not appear to worsen or induce tics. Concerta is contraindicated in patients with marked anxiety, tension, and agitation because it may aggravate these symptoms. It should not be used in patients with glaucoma, motor tics, or a diagnosis or family history of Tourette's syndrome. It is contraindicated during treatment with monoamine oxidase inhibitors, and it should not be given until at least 14 days after such treatment has been discontinued (hypertensive crises may result). He said these data "clearly demonstrate the safety of once-daily methylphenidate for up to two years."

Two other studies also demonstrated the effectiveness of a new formulation of methylphenidate, dexmethylphenidate HC1 (Focalin, Novartis). One study in 132 patients six to 17 years of age showed that treatment effects could be achieved at half the dose. A second study, in 89 ADHD patients, showed that patients achieved substantial reduction of symptoms over a 44-week period that followed a six-week open-label dose-titration, a doubleblind, placebo-controlled two-week withdrawal period, and then a 44week open-label extension to determine long-term safety and efficacy.

Keith Corners, Ph.D., professor emeritus of psychiatry and behavioral sciences at Duke University Medical Center, said that the results "signify that dexmethylphenidate HCl, which contains only the active d-isomer, is a safe and effective treatment for ADHD at half the dose of methylphenidate."

An open-label, community assessment of a formulation consisting of mixed salts of q and 1-amphetamine, designed to produce a pulse release of the medication Adderall XR (amphetamine and dextroamphetamine, Shire) for pediatric ADHD, produced significant improvement in symptoms after it was switched from other ADHD medications, according to Paul Ambrosini, M.D., of Hahnemann University in Philadelphia.

For anxiety/depression

Generalized anxiety disorder (GAD) afflicts about 2.8% of adults and about 5% of children. An experimental epilepsy drug, pregabalin (Pfizer), was shown to achieve a more rapid and sustained response than alprazolam in a four-week, double-blind, placebo-controlled; trial in 455 patients with moderate to severe GAD.

Mark Pollack, study investigator and director of the anxiety disorders program at Massachusetts General Hospital, said that "pregabalin appears to have a more rapid onset compared with antidepressants." He added that it also appears to have less of a chance of creating physical dependence and to cause less sedation and cognitive impairment than is the case with the benzodiazepines.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

A New Look at Treating Some Old Mental Disorders


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?